CORRECTION
Correction: Efficacy and Safety Assessment
of the Addition of Bevacizumab to Adjuvant
Therapy Agents in Cancer Patients: A
Systematic Review and Meta-Analysis of
Randomized Controlled Trials
Fariba Ahmadizar, N. Charlotte Onland-Moret, Anthonius de Boer, Geoffrey Liu, Anke
H. Maitland-van der Zee
The phrases
“
log hazard ratio
”
and
“
log HR
”
appear incorrectly throughout the article and
Sup-porting Information files, with the exception of the
“
Data analysis
”
subsection, Fig 5, and Fig 6.
The correct terminology in all other cases should be
“
hazard ratio
”
and
“
HR.
”
Reference
1. Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH (2015) Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A System-atic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 10(9): e0136324. doi:10. 1371/journal.pone.0136324PMID:26331473
PLOS ONE | DOI:10.1371/journal.pone.0141704 October 22, 2015 1 / 1
OPEN ACCESS
Citation:Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH (2015) Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 10(10): e0141704. doi:10.1371/journal.pone.0141704
Published:October 22, 2015
Copyright:© 2015 Ahmadizar et al. This is an open access article distributed under the terms of the
